Salpingectomy

Salpingectomy has been studied in 13 papers since 2022: 2 observational studies in people, 9 reviews; 8 in the past year. The newest paper, Nov 9, 2026: “Risk‐reducing gynecologic surgery in hereditary cancer: Evidence, timing, and counseling”.

Intervention

13 papers study it12 findingsUpdated

MeSH

1 new paper in 30 daysSee all 13 papers on salpingectomy

At a glance

Reviews describe lower epithelial ovarian cancer risk with salpingectomy and prevention of high-grade serous carcinoma in average-risk women. One group reports an association with menopausal age in postmenopausal women. Modeling projects gains in quality-adjusted life-years at general-population risk but no clear cost-effectiveness benefit in that setting.

12 findings in 8 papers from 2022 to 2026, 3 of them since June 2026

The findings reach people, from one lab or study. 3 independent labs in 2 countries.

“In all the models, education, history of salpingectomy, diabetes, cardiac ischemic, and depression were significantly associated with menopausal age.”
Evaluation of multiple linear regression function and generalized linear model types in estimating natural menopausal age: A cross-sectional studyInternational journal of reproductive biomedicine2022doi:10.18502/ijrm.v20i5.11052

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 3 independent labs in 2 countries
  • Funders: Break Through Cancer and 8 more
  • 2 of 4 findings with company ties
  • Humans2
  • In silico1

What did studies of salpingectomy find?

6

Studies of salpingectomy measured 6 outcomes, among them Cost-effectiveness, quality-adjusted life-years and ovarian cancer.

Cost-effectiveness

upin silico1no changein silico1

1 study
  1. Salpingectomy improves cost-effectiveness in silico (relative risk 1.5) (ICERs $142,516-$172,112/QALY).

    “At a moderately increased risk (relative risk 1.5), ICERs fell to $142,516-$172,112/QALY, making salpingectomy cost-effective at ages 45 and 50.”

    In silicorelative risk 1.5

    Standalone Salpingectomy for Primary Ovarian Cancer Prevention: A Cost-Effectiveness Analysis

    American journal of obstetrics and gynecology

  2. Salpingectomy showed no clear effect on cost-effectiveness in silico (general population risk) (ICERs $239,736-$288,870/QALY).

    “For general population risk, standalone salpingectomy was not cost-effective in any age cohort”

    In silicogeneral population risk

    Standalone Salpingectomy for Primary Ovarian Cancer Prevention: A Cost-Effectiveness Analysis

    American journal of obstetrics and gynecology

Quality-adjusted life-years

upin silico1

1 study
  1. Salpingectomy increases quality-adjusted life-years in silico (general population risk) (0.02-0.03 QALYs).

    “Incremental costs were approximately $6100-$6225 per person with gains of 0.02-0.03 QALYs.”

    In silicogeneral population risk

    Standalone Salpingectomy for Primary Ovarian Cancer Prevention: A Cost-Effectiveness Analysis

    American journal of obstetrics and gynecology

Ovarian cancer

downin humans1

1 study
  1. Salpingectomy prevents ovarian cancer in humans during indicated benign surgery.

    “Opportunistic salpingectomy during indicated benign surgery is supported as an ovarian cancer prevention strategy that preserves ovarian hormonal function”

    Reviewduring indicated benign surgery

    Complex benign gynecology in perimenopause: current evidence and future directions

    Current opinion in obstetrics & gynecology

More on Ovarian cancer

High-grade serous carcinoma

downin humans1

1 study
  1. Salpingectomy prevents high-grade serous carcinoma in average-risk women.

    “Opportunistic salpingectomy prevents HGSC in average-risk women”

    Reviewin average-risk women

    Serous tubal intraepithelial carcinoma-looking into the earliest events of ovarian cancer development

    Academia oncology

More on High-grade serous carcinoma

Ovary

no changein humans1

1 study
  1. Salpingectomy showed no clear effect on ovary in humans.

    “Bilateral salpingectomy has been demonstrated to be safe with minimal added operative time, no adverse effects on ovarian function”

    Reviewbilateral salpingectomyovaryfemales

    FIGO position statement on opportunistic salpingectomy as an ovarian cancer prevention strategy

    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

Age at menopause onset

no changein humans1

1 study
  1. Salpingectomy showed no clear effect on age at menopause onset in humans.

    “Studies have demonstrated that salpingectomy was safe, cost-effective, and was not associated with an earlier age of menopause onset.”

    Reviewfemales

    Salpingectomy for the Primary Prevention of Ovarian Cancer: A Systematic Review

    JAMA surgery

What is salpingectomy linked with?

4

Studies link salpingectomy with 4 measures, among them epithelial ovarian cancer, epithelial ovarian cancer incidence and ovarian cancer.

Epithelial ovarian cancer

downin humans2

2 studies
  1. Salpingectomy lowers the risk of epithelial ovarian cancer in humans.

    “supporting the benefit of complete, bilateral salpingectomy at the time of obstetric and gynecologic surgery”

    Review

    ACOG Clinical Practice Update: Salpingectomy for the Prevention of Epithelial Ovarian Cancer

    Obstetrics and gynecology

  2. Salpingectomy lowers the risk of epithelial ovarian cancer in average-risk women.

    “Studies show that bilateral salpingectomy (BS) significantly reduces ovarian cancer incidence even in average-risk women.”

    Reviewin average-risk womenbilateral salpingectomyfemales

    FIGO position statement on opportunistic salpingectomy as an ovarian cancer prevention strategy

    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

More on Epithelial ovarian cancer

Epithelial ovarian cancer incidence

downin humans1RR 0.223

1 study
  1. Salpingectomy is associated with epithelial ovarian cancer incidence in humans (compared with controls without salpingectomy) (77.7% reduction; RR 0.223, 95% CI 0.182–0.274).

    “Salpingectomy was associated with a 77.7% reduction in EOC incidence compared to control patients”

    Reviewcompared with controls without salpingectomyfemales

    Meta-analysis of changes in epithelial ovarian cancer incidence rates associated with salpingectomy: A comparison of 2022-2023 and earlier periods

    Journal of the Turkish German Gynecological Association

More on Epithelial ovarian cancer incidence

Ovarian cancer

downin humans1−80% lower ovarian cancer risk

1 study
  1. Salpingectomy is associated with ovarian cancer in humans (Approximately 80% lower ovarian cancer risk).

    “Salpingectomy has been associated with ovarian cancer risk reduction of approximately 80%.”

    Reviewfemales

    Salpingectomy for the Primary Prevention of Ovarian Cancer: A Systematic Review

    JAMA surgery

More on Ovarian cancer

Menopausal age

mixedin humans1

1 study
  1. Salpingectomy is associated with menopausal age in humans (postmenopausal women).

    “In all the models, education, history of salpingectomy, diabetes, cardiac ischemic, and depression were significantly associated with menopausal age.”

    Humanspostmenopausal womenfemalesn = 1,251

    Evaluation of multiple linear regression function and generalized linear model types in estimating natural menopausal age: A cross-sectional study

    International journal of reproductive biomedicine

Funding

6 grants since 2019

Agency for Healthcare Research and Quality$3.6MGouvernement du Canada | Canadian Institutes of Health ResearchCA$584KMedical Research Future FundA$2M

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    A modeling study reports increased quality-adjusted life-years with salpingectomy at general-population risk, but no cost-effectiveness benefit there; cost-effectiveness improves at relative risk 1.5. A review describes lower epithelial ovarian cancer risk in humans. The Agency for Healthcare Research and Quality is named as a grant funder.

  2. Summary written from the findings.

Latest

Dec 2025: 0Jan 2026: 1Feb 2026: 2Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 1Jul 2026: 0Aug 2026: 1Sep 2026: 2Oct 2026: 0Nov 2026: 18 papers in 12 months

See all 13 papers on salpingectomy